A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for N...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4466375?pdf=render |
| _version_ | 1818133212430336000 |
|---|---|
| author | Qing Zhang Yang Zhang Ke Li Haiyu Wang Huizhong Li Junnian Zheng |
| author_facet | Qing Zhang Yang Zhang Ke Li Haiyu Wang Huizhong Li Junnian Zheng |
| author_sort | Qing Zhang |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. We showed that the rates of positive expression of αvβ3, αvβ5 and NRP-1 in the A549 cell line were 68.5%, 35.3% and 94.5%, respectively. The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. The rates of growth inhibition of the tumors of the iRGD group, the Gemcitabine group and the Gemcitabine+iRGD group were 8%, 59.8% and 86.9%, respectively. The results of mechanism studies showed that PCNA expression in the Gemcitabine+iRGD group decreased 71.5% compared with that in Gemcitabine group. The rate of apoptosis in the Gemcitabine+iRGD group was 2.2 time that of the Gemcitabine group. Therefore, the tumor-penetrating Peptide iRGD can enhance the tumor-penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft. The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC. |
| first_indexed | 2024-12-11T08:49:08Z |
| format | Article |
| id | doaj.art-34825ce866e644fca288ef7289dbef94 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T08:49:08Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-34825ce866e644fca288ef7289dbef942022-12-22T01:14:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e012986510.1371/journal.pone.0129865A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.Qing ZhangYang ZhangKe LiHaiyu WangHuizhong LiJunnian ZhengNon-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. We showed that the rates of positive expression of αvβ3, αvβ5 and NRP-1 in the A549 cell line were 68.5%, 35.3% and 94.5%, respectively. The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. The rates of growth inhibition of the tumors of the iRGD group, the Gemcitabine group and the Gemcitabine+iRGD group were 8%, 59.8% and 86.9%, respectively. The results of mechanism studies showed that PCNA expression in the Gemcitabine+iRGD group decreased 71.5% compared with that in Gemcitabine group. The rate of apoptosis in the Gemcitabine+iRGD group was 2.2 time that of the Gemcitabine group. Therefore, the tumor-penetrating Peptide iRGD can enhance the tumor-penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft. The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC.http://europepmc.org/articles/PMC4466375?pdf=render |
| spellingShingle | Qing Zhang Yang Zhang Ke Li Haiyu Wang Huizhong Li Junnian Zheng A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. PLoS ONE |
| title | A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. |
| title_full | A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. |
| title_fullStr | A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. |
| title_full_unstemmed | A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. |
| title_short | A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. |
| title_sort | novel strategy to improve the therapeutic efficacy of gemcitabine for non small cell lung cancer by the tumor penetrating peptide irgd |
| url | http://europepmc.org/articles/PMC4466375?pdf=render |
| work_keys_str_mv | AT qingzhang anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT yangzhang anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT keli anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT haiyuwang anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT huizhongli anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT junnianzheng anovelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT qingzhang novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT yangzhang novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT keli novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT haiyuwang novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT huizhongli novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd AT junnianzheng novelstrategytoimprovethetherapeuticefficacyofgemcitabinefornonsmallcelllungcancerbythetumorpenetratingpeptideirgd |